Skip to main content

Table 3 Dose modification of valaciclovir according to creatinine clearance

From: Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial

Creatinine clearance (CrCl ml/min)a Valaciclovir dose
>75 2 g four times a day
51–75 1.5 g four times a day
26–50 1.5 g three times a day
10–25 1.5 g two times a day
  1. aTests performed within 6 months of the pre-baseline visit can be used for this assessment